New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
07:17 EDTHSKA, IDXX, CBST, LLYLeerink to host a conference
November Management Access Days Conference is being held in Boston on November 19-20.
News For LLY;IDXX;HSKA;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 30, 2015
07:20 EDTLLYEli Lilly CEO Lechleiter says currency fluctuations hitting topline
Subscribe for More Information
07:04 EDTIDXXIDEXX sees FY15 adjusted EPS $4.33-$4.43, consensus $4.39
Subscribe for More Information
07:04 EDTIDXXIDEXX reports Q4 EPS 54c, may not be comparable to consensus 80c
EPS includes impacts related to the transition to the all-direct CAG Diagnostics sales approach in the US of 41c per share for the fourth quarter; Reports Q4 revenue $351.96M, consensus $373.18M
06:38 EDTLLYEli Lilly reports Q4 Cialis sales $622.4M vs. $588.3M last year
Subscribe for More Information
06:30 EDTLLYEli Lilly FY15 EPS guidance does not include 12c potential charge
Subscribe for More Information
06:28 EDTLLYEli Lilly backs FY15 EPS view of $3.10-$3.20, consensus $3.18
Lowers FY15 revenue guidance to $19.5B-$20B from $20.3B-$20.8B, consensus $20.67B.
06:26 EDTLLYEli Lilly reports Q4 EPS 75c, consensus 74c
Subscribe for More Information
January 29, 2015
15:37 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
13:36 EDTLLYEli Lilly volatility elevated into Q4 and outlook
Subscribe for More Information
13:29 EDTLLYEarnings Preview: Eli Lilly to report Q4 results amid new product launches
Subscribe for More Information
12:00 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.
09:06 EDTHSKAHeska signs distribution agremeent with scil animal care company
Subscribe for More Information
January 22, 2015
07:54 EDTIDXXIDEXX price target raised to $175 from $160 at Canaccord
Subscribe for More Information
07:38 EDTCBSTARIAD appoints DesRosier as Chief Legal and Administrative Officer
Subscribe for More Information
January 21, 2015
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
08:02 EDTCBSTMerck completes tender offer to acquire Cubist
Merck (MRK) announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals (CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7% of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares. Following consummation of the tender offer, Merck expects to complete the acquisition of Cubist later today through a merger of Merckís wholly owned subsidiary with and into Cubist without stockholder approval. Upon completion of the merger, all outstanding shares of common stock of Cubist, other than shares held by Cubist in treasury or shares held by Cubistís stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $102.00 offer price per share without interest, less any applicable withholding taxes. In addition, upon completion of the merger, Cubist will become a wholly owned subsidiary of Merck and the common stock of Cubist will cease to be traded on the NASDAQ Stock Market.
January 20, 2015
17:18 EDTCBSTDana Holding to replace Cubist in S&P 400 as of 1/22 close
Subscribe for More Information
10:20 EDTCBSTOptions with decreasing implied volatility
Options with decreasing implied volatility: RPRX TLM BBY GME CBST NPSP
January 16, 2015
10:15 EDTCBSTOptions with decreasing implied volatility: BBY ETE CBST
Subscribe for More Information
08:46 EDTIDXXIDEXX price target raised to $178 from $155 at Stifel
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use